The Role of Syndromic Testing in the
Era of COVID-19
Select Science | bioMérieux Expert: Christine Ginocchio, PhD, MT(ASCP), VP, Global Medical Affairs, bioMérieux/BioFire
Common respiratory pathogens are starting to reemerge as the country loosens pandemic restrictions and people return to many of their previous routines. Being able to detect whether an ill patient has COVID-19 or something else will be key in maintaining the progress that we have made thus far. Syndromic testing was utilized early in the pandemic before the frontline tests even included SARS-CoV-2, and now as we enter the respiratory viral season, tests such as the BioFire RP2.1 Panel (EUA) with SARS-CoV-2, are maximizing hospital efficiency by testing for common pathogens such as influenza in addition to COVID-19.
Read the full article on Select Science®. Learn more about the BioFire® Respiratory 2.1 (RP2.1) Panel (EUA). BioFire is a bioMérieux company.